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Objectives This study aimed to evaluate whether CHADS2 and CHA2DS2-VASc scores are useful for risk stratification in pa-
tients after catheter ablation of atrial fibrillation (AF).
Background AF is associated with increased risk of cardiovascular events. However, limited data are available on the predic-
tors of adverse events in patients with AF after catheter ablation.
Methods A total of 565 patients with AF who underwent catheter ablation were enrolled in the study. The clinical end-
point was occurrence of thromboembolic events (ischemic stroke, transient ischemic attack, peripheral embo-
lism, or pulmonary embolisms) or death during follow-up after catheter ablation.
Results During a follow-up of 39.2  22.6 months, 27 patients (4.8%) experienced adverse events. Both the CHADS2
and CHA2DS2-VASc scores were useful predictors of events in separate multivariate models. The areas under the
receiver-operator characteristic curves based on the CHADS2 and CHA2DS2-VASc scores in predicting events
were 0.785 and 0.830, respectively. Although the difference did not reach statistical significance (p  0.116),
the CHA2DS2-VASc score could be used to further stratify the patients with CHADS2 scores of 0 or 1 into 2
groups with different event rates (7.1% vs. 1.1%, p  0.003) at a cutoff value of 2.
Conclusions The CHADS2 and CHA2DS2-VASc scores are useful predictors of adverse events after catheter ablation of AF. (J Am Coll
Cardiol 2011;58:2380–5) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.045wAtrial fibrillation (AF) is a common arrhythmia that repre-
sents an independent risk factor for strokes and is associated
See page 2386
with marked morbidity and mortality (1). Recently, a newly
developed scoring system, the CHA2DS2-VASc score,
hich extends the CHADS2 scheme by considering addi-
From the *Division of Cardiology, Department of Medicine, Taipei Veterans General
Hospital, Taipei, Taiwan; †Institute of Clinical Medicine and Cardiovascular
Research Center, National Yang-Ming University, Taipei, Taiwan; ‡Division of
Cardiology, Department of Internal Medicine, National Defense Medical Center and
Tri-Service General Hospital, Taipei, Taiwan; §Department of Medicine, Division of
Cardiology, Cheng Hsin General Hospital, Taipei, Taiwan; Division of Cardiology,
National Yang Ming University Hospital, I-Lan, Taiwan; ¶School of Medicine,
Chung-Shan Medical University, Taichung, Taiwan; and the #Department of
Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical
Sciences, Hiroshima, Japan. The authors have reported that they have no relationships
relevant to the contents of this paper to disclose.Manuscript received February 20, 2011; revised manuscript received August 9,
2011, accepted August 21, 2011.tional stroke risk factors, was recommended to guide anti-
thrombotic therapy in patients with AF (2,3). However,
these 2 scoring systems were developed and validated in AF
patients who did not receive catheter ablations. This study
aimed to investigate whether the CHADS2 or CHA2DS2-
VASc score is useful for predicting thromboembolic events
and mortality after catheter ablation for AF.
Methods
A total of 565 consecutive patients with symptomatic
drug-refractory AF who received radiofrequency catheter
ablation were enrolled in the study. The CHADS2 score
as calculated for each patient (4). The CHA2DS2-VASc
score was calculated for every patient based on a point
system in which 2 points were assigned for a history of
stroke or transient ischemic attack (TIA) or age 75 years.
One point was assigned for age between 65 and 74 years;
history of hypertension, diabetes, recent cardiac failure, and
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plaque, or peripheral artery disease); and female sex (2).
Catheter ablation of AF and anticoagulant strategy. Be-
fore catheter ablation, every patient underwent transesoph-
ageal echocardiography to confirm the absence of a left atrial
thrombus. Details of ablation procedures are provided in the
Online Appendix.
Before catheter ablation, the use of oral anticoagulation
therapy with an adjusted dose of warfarin was based on the
patients’ CHADS2 scores. Warfarin was intended to be
rescribed for patients whose CHADS2 scores were 2 to
aintain the international normalized ratio (INR) of the
rothrombin time between 2 and 3 (3). After catheter
blation, warfarin was continued for 3 months for patients
ho were already receiving warfarin treatment before abla-
ion. After 3 months, discontinuation of warfarin was
enerally not considered for patients with CHADS2 scores
of 2. However, if patients remained symptom free, and
there was no evidence of AF recurrences, replacement of
warfarin with antiplatelet agents was considered. This was
Baseline Characteristics of theP ti nts With and Without Adverse EventsTable 1 B seline Charact ristics of thePatients With and Without Adverse Events
Variable
With Events
(n  27)
Without Events
(n  538) p Value
Age, yrs 67.8 12.7 53.5 12.0 0.001
Age 65 yrs 59.3% 17.8% 0.001
Age 75 yrs 40.7% 3.0% 0.001
Male 77.8% 72.3% 0.534
Medical history
Hypertension 74.1% 45.0% 0.003
Diabetes mellitus 25.9% 11.9% 0.065
Congestive heart failure 33.3% 6.5% 0.001
Coronary artery disease 66.7% 27.1% 0.001
Previous stroke/TIA 25.9% 4.1% 0.001
Previous vascular disease 7.4% 1.1% 0.052
Long-term use of warfarin 7.4% 3.2% 0.216
Left atrial diameter, mm 45.5 11.8 39.1 6.7 0.001
LVEF, % 52.7 11.0 58.9 7.7 0.008
AF type (paroxysmal AF) 48.1% 79.4% 0.001
Recurrence rate after ablations 59.3% 28.1% 0.001
CHADS2 score 2 (1–3) 1 (0–1) 0.001
CHA2DS2-VASc score 3 (2–4) 1 (0–2) 0.001
Values are mean  SD, %, or median (interquartile range).
AF atrial fibrillation; LVEF left ventricular ejection fraction; TIA transient ischemic attack.
Univariate Cox Regression Analysis forPredictors of Adv rse Events After Catheter AblationTable 2 Uni a iate C x Regr sion Analysis forPredictors of Adverse Events After Catheter Ablation
Variable Hazard Ratio 95% CI p Value
AF type (nonparoxysmal) 4.682 2.186–10.030 0.001
Recurrence after multiple ablations 3.552 1.648–7.655 0.001
Left atrial diameter, mm 1.077 1.047–1.108 0.001
LVEF, % 0.920 0.885–0.956 0.001
CHADS2 score 2.154 1.768–2.624 0.001
CHA2DS2-VASc score 1.856 1.585–2.174 0.001CI  confidence interval; other abbreviations as in Table 1.
rdecided by the physicians re-
sponsible for treatment accord-
ing to the individual characteris-
tics of each patient.
Definitions of the clinical end-
points and follow-up. The clini-
cal endpoint was the combined
occurrence of clinical events, in-
cluding thromboembolic events
(ischemic stroke, TIA, peripheral
embolism, or pulmonary embo-
lism) and death. Patients were followed-up every 1 to 3 months
at our cardiology clinic or by referring physicians after catheter
ablation. During each follow-up, patients were carefully
examined, and 24-h Holter monitoring and/or cardiac event
recording for 1 week were performed. AF recurrence was
defined as an episode lasting longer than 1 min and
confirmed by electrocardiograms 2 months after ablation.
The status of patients who did not receive regular follow-up
was assessed by chart reviews and telephone consultations to
determine whether adverse events occurred. Our database
was linked with the National Death Registry, and mortal-
ities were further validated through a unique, lifelong
personal identification number given to every Taiwan
citizen.
Statistical analysis. Differences between continuous values
were assessed using an unpaired 2-tailed t test for normally
distributed continuous variables, the Mann-Whitney U test
for skewed variables, and the chi-square test for nominal
variables. Cox regression analysis was used to identify
factors associated with adverse events. Details of the statis-
tical analysis are provided in the Online Appendix.
Results
Clinical characteristics, adverse events, and predictors.
Baseline characteristics of patients with and without events
are shown in Table 1. During the follow-up period of
39.2 22.6 months, 27 patients (4.8%) experienced adverse
events, including death in 9 patients, ischemic stroke in 9,
TIA in 6, pulmonary embolisms in 2, and peripheral
embolism in 1. Three of the 27 patients experienced events
within the blanking period after catheter ablation. Signifi-
cant predictors of adverse events based on the univariate
Multivariate Cox Regression Analysisfor Predictors f Adverse Events AfterCatheter Ablation Using the CHADS2 Score
Table 3
Multivariate Cox Regres ion Analysis
for Predictors of Adverse Events After
Catheter Ablation Using the CHADS2 Score
Variable Hazard Ratio 95% CI p Value
AF type (nonparoxysmal) 1.804 0.752–4.328 0.186
Recurrence after multiple ablations 2.452 1.060–5.673 0.036
Left atrial diameter, mm 1.015 0.982–1.050 0.379
LVEF, % 0.977 0.936–1.021 0.308
CHADS2 score 1.892 1.482–2.414 0.001
Variables with p  0.05 in Table 2 were adjusted with the CHADS2 score in the multivariate Cox
Abbreviations
and Acronyms
AF  atrial fibrillation
INR  international
normalized ratio
ROC  receiver-operator
characteristic
TIA  transient ischemic
attackegression analysis.
Abbreviations as in Tables 1 and 2.
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CHADS2 and CHA2DS2-VASc scores remained indepen-
ent predictors of adverse events in separate multivariate
odels (Tables 3 and 4). Besides the CHADS2 and
CHA2DS2-VASc scores, AF recurrence after multiple pro-
cedures was a significant predictor of adverse events. The
event rate was higher in patients with recurrences than in
patients without recurrences (9.6% vs. 2.8%, p  0.001).
When events were further divided into ischemic stroke/
TIA, other embolic events, and death, the CHADS2 and
CHA2DS2-VASc scores remained significant predictors.
Hazard ratios of each increment of the CHADS2 scores to
predict ischemic stroke/TIA, other embolic events, and
death were 1.893 (95% confidence interval [CI]: 1.364 to
2.627, p  0.001), 2.306 (95% CI: 1.116 to 4.764, p 
0.024), and 1.786 (95% CI: 1.159 to 2.754, p  0.009),
respectively. Similarly, hazard ratios of each increment of
the CHA2DS2-VASc scores to predict ischemic stroke/
IA, other embolic events, and death were 1.694 (95% CI:
.321 to 2.173, p  0.001), 2.088 (95% CI: 1.1865 to
.6789, p  0.011), and 1.551 (95% CI: 1.108 to 2.171,
 0.010), respectively. The usefulness of these 2 scoring
ystems in predicting strokes/TIAs was consistent in pa-
ients with and without recurrences.
HADS2 and CHA2DS2-VASc scores for prediction of
dverse events. The event rates of patients continuously
ncreased with increases in the CHADS2 and CHA2DS2-
ASc scores (Fig. 1). Figure 2 shows the receiver-operator
haracteristic (ROC) curves for predicting events after
atheter ablation based on the CHADS2 and CHA2DS2-
ASc scores. At a cutoff point of 2 identified by the ROC
urve, Kaplan-Meier survival analysis showed that patients
ith CHADS2 scores of 2 (sensitivity, 59.3%; specificity,
83.5%) were associated with a higher event rate than the
patients with CHADS2 scores of 2 (15.2% vs. 2.4%, p 
0.001) during the follow-up period (Fig. 3A). Furthermore,
a CHA2DS2-VASc score of 2 identified by the ROC
urve (sensitivity, 85.2%; specificity, 66.5%) also signifi-
antly predicted occurrences of events (11.3% vs. 1.1%, p 
.001) (Fig. 3B).
HA2DS2-VASc scores and adverse events in low-risk
patients with CHADS2 scores of 0 or 1. In the subgroup
Multivariate Cox Regression Analysisfor Predictors f Adverse Events AfterCatheter Ablation Using the CHA2DS2-VASc Score
Table 4
Multivariate Cox Regres ion Analysis
for Predictors of Adverse Events After
Catheter Ablation Using the CHA2DS2-VASc Score
Variable Hazard ratio 95% CI p Value
AF type (nonparoxysmal) 1.927 0.800–4.644 0.144
Recurrence after multiple ablations 2.292 1.015–5.276 0.047
Left atrial diameter, mm 1.018 0.985–1.053 0.281
LVEF, % 0.973 0.931–1.017 0.219
CHA2DS2-VASc score 1.678 1.393–2.021 0.001
Variables with p 0.05 in Table 2 were adjusted with the CHA2DS2-VASc score in the multivariate
Cox regression analysis.
Abbreviations as in Tables 1 and 2.analysis of 460 patients with CHADS2 scores of 0 or 1, 11(2.4%) patients experienced adverse events. The event rate
progressively increased from 0.6% in patients with
CHA2DS2-VASc scores of 0 to 11.8% in patients with
CHA2DS2-VASc scores of 3 (Fig. 4). Using a CHA2DS2-
VASc score of 2 as the cutoff point, patients with
CHA2DS2-VASc scores of 2 were associated with a
higher event rate as compared with patients whose
CHA2DS2-VASc scores were 2 (7.1% vs. 1.1%, p 
0.003) (Fig. 5).
Discussion
Main findings. The main findings were as follows:
CHADS2 and CHA2DS2-VASc scores were useful param-
eters for predicting adverse events after catheter ablation of
AF; and the CHA2DS2-VASc score was helpful in further
risk stratifications among patients with CHADS2 scores of
or 1.
Figure 1 Event Rates and Scores
The adverse event rates continuously increased when the CHADS2 (A)
and CHA DS -VASc (B) scores became higher.2 2
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November 29, 2011:2380–5 Risk Scores and Adverse Events After AF AblationCHADS2 and CHA2DS2-VASc scores and adverse
vents after catheter ablation. In the current study, both
cores proved to be useful predictors of events after catheter
blation of AF in separate multivariate models. These results
rovide evidence for extending the usefulness of CHADS2 and
CHA2DS2-VASc scores to predict adverse events in AF
atients who have received catheter ablation. In view of the
OC curves based on the CHADS2 and CHA2DS2-VASc
cores in predicting events, the differences between the areas
nder the curves did not reach statistical significance (p 
.116). This may be because of the low event rate of the current
Figure 2 ROC Curves for the CHADS2 and
CHA2DS2-VASc Scores for Predicting Events
The areas under the curves (AUCs) for the CHADS2 (A) and CHA2DS2-VASc
(B) scores for predicting adverse events were 0.785 and 0.830, respectively (p 
0.116). ROC  receiver-operator characteristic.tudy. Therefore, further trials with a larger sample size may beble to demonstrate a significant statistical difference with
ufficient power.
Although the predictive accuracies of the CHADS2 and
HA2DS2-VASc scores assessed by the ROC curves did not
iffer significantly, the CHA2DS2-VASc scores could further
stratify the patients with CHADS2 scores of 0 or 1 into 2
roups with different risks of events at the cutoff value of 2.
ccording to the flowchart of the current guidelines of the
uropean Society of Cardiology on the use of oral anticoagu-
ants after catheter ablations, the CHADS2 scheme should be
sed as a simple initial means of assessing stroke risk, and
hronic oral anticoagulant therapy is recommended for patients
ith CHADS2 scores of 2. For patients with a CHADS2
score of 0 or 1, it is recommended that the CHA2DS2-VASc
scoring system be used for a more comprehensive assessment of
the risks (3). However, this recommendation was mainly based
on consensus among experts, and the data in patients who
received catheter ablation of AF were insufficient. The results
Figure 3 Event-Free Survival Curves for Patients With
Different CHADS2 and CHA2DS2-VASc Scores
Kaplan-Meier survival analysis showed that the patients with CHADS2 scores of
2 were associated with a higher event rate compared with the patients with
CHADS2 scores of 2 (15.2% vs. 2.4%, p  0.001) (A). Furthermore, a CHA2DS2-
VASc score of 2 identified by the receiver-operator characteristic curve also sig-
nificantly predicted occurrences of events (11.3% vs. 1.1%, p  0.001) (B).
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the previously mentioned flowchart.
Clinical applications of CHADS2 and CHA2DS2-VASc
scores. Oral et al. (5) reported that discontinuation of
anticoagulant therapy appears to be safe after successful
ablation of AF. Recently, Bunch et al. (6) reported that
among patients with AF, the stroke risk was lower in
Figure 4 Event Rates in the Patients
With CHADS2 Scores of 0 or 1
The event rates progressively increased from 0.6% to 11.8%
in patients with different CHA2DS2-VASc scores.
Figure 5 Flowchart of Event Rates and Scores
A flowchart demonstrating the event rates in the patients stratified according to thpatients who underwent catheter ablation than in those who
did not. The 3-year stroke rate (2% to 3%) was similar to
that of our study. However, these previous studies did not
provide a useful method to identify patients with high risk
of events. According to the results of the present study, the
CHADS2 scoring scheme can be used to screen patients
with CHADS2 scores of2 who are predisposed to adverse
vents after catheter ablation. Furthermore, a more detailed
HA2DS2-VASc scoring scheme can further identify pa-
tients with risk of events among patients with CHADS2
scores of 2. The clinical use of CHA2DS2-VASc scores
hould be emphasized because among patients with
HADS2 scores of 0 or 1 who were traditionally assumed to
e at low risk, those with CHA2DS2-VASc scores of 3 can
ave an event rate as high as 11.8%. Among the 9 patients
ho experienced stroke, 2 patients were receiving long-term
edication with warfarin and had an INR within the
herapeutic range at the time the events occurred. Five and
patients had CHADS2 and CHA2DS2-VASc scores of
2, respectively. Of the 4 patients with CHADS2 scores of
or 1, 3 had CHA2DS2-VASc scores of 2. This may
urther demonstrate the important role of the CHA2DS2-
VASc score in identifying low-risk patients who are at risk
of stroke; an anticoagulant should be prescribed to lower
this risk. Furthermore, for patients with scores indicating a
high risk of stroke and who are receiving warfarin treatment,
it may be helpful to monitor the INR level more closely to
avoid suboptimal treatment. However, a further prospective
and large-scale trial is necessary to prove this supposition.
DS and CHA DS -VASc scores.e CHA 2 2 2
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November 29, 2011:2380–5 Risk Scores and Adverse Events After AF AblationStudy limitations. First, although the follow-up was not
niform for every patient, more than 70% of the study
opulation underwent follow-up regularly at the cardiol-
gy clinics, and the remaining patients were completely
ssessed through telephone consultations. The accuracy
f mortality events was further confirmed through the
ational Death Registry of Taiwan. Second, the strategy
bout the use of warfarin was determined by the physi-
ians responsible for treatment according to the individ-
al characteristics of each patient. However, the manage-
ent was based on the same principle for individuals with
imilar risk. Moreover, long-term use of warfarin after
atheter ablation was not a significant predictor of
dverse events based on the analysis and therefore may
ot confound the results of the present study. Last,
lthough only 18.6% of the patients in the study had
HADS2 scores 2, the mean person-years of follow-up
was 1,500, which was sufficient to show statistical
significance in a population with low event rates.
Conclusions
CHADS2 and CHA2DS2-VASc scores can provide an
stimate of the risk of adverse events in patients who
ndergo catheter ablation of AF. Among patients with
HADS2 scores of 0 or 1, CHA2DS2-VASc scores were
seful to further identify which patients were predisposed to
dverse events.Reprint requests and correspondence: Drs. Shih-Ann Chen and/or
Tsu-Juey Wu, Division of Cardiology, Department of Medicine,
Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai
Road, Taipei, Taiwan. E-mail: epsachen@ms41.hinet.net or
tjwu@mail.vghtc.gov.tw.
REFERENCES
1. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation
on mortality, stroke, and medical costs. Arch Intern Med 1998;158:
229 –34.
2. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratifica-
tion for predicting stroke and thromboembolism in atrial fibrillation
using a novel risk factor-based approach: the Euro heart survey on atrial
fibrillation. Chest 2010;137:263–72.
3. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management
of atrial fibrillation: the Task Force for the Management of Atrial
Fibrillation of the European Society of Cardiology (ESC). Eur Heart J
2010;31:2369–429.
4. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical
classification schemes for predicting stroke: results from the National
Registry of Atrial Fibrillation. JAMA 2001;285:2864–70.
5. Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events
after percutaneous left atrial radiofrequency ablation of atrial fibrillation.
Circulation 2006;114:759–65.
6. Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter
ablation for atrial fibrillation have long-term rates of death, stroke, and
dementia similar to patients without atrial fibrillation. J Cardiovasc
Electrophysiol 2011;22:839–45.
Key Words: atrial fibrillation y catheter ablation y CHADS2 score y
CHA2DS2-VASc score.
APPENDIX
For an expanded Methods section,
please see the online version of this article.
